Disease · HP_0000708

Atypical behavior

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Atypical behavior. Diseases, record HP_0000708. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000708

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Atypical behavior
Open Targets ID: HP_0000708
Other names: Behavioral abnormality, Behavioral changes, Behavioral disorders, Behavioral disturbances, Behavioral problems, Behavioral symptoms, Behavioral/psychiatric abnormalities, Behavioural abnormality, Behavioural changes, Behavioural disorders, Behavioural disturbances, Behavioural problems, Behavioural symptoms, Behavioural/Psychiatric abnormality, Psychiatric disorders, Psychiatric disturbances
Highest stage of its drugs: Phase 3, for 4 of its 17 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RISPERIDONE	CHEMBL85	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
ASCORBIC ACID	CHEMBL196	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
BIFEPRUNOX	CHEMBL218166	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VITAMIN E	CHEMBL3989727		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
BUPRENORPHINE	CHEMBL511142	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
MORPHINE	CHEMBL70	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREGABALIN	CHEMBL1059	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets115

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CNR1	Cannabinoid receptor 1	2	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets
DRD2	D(2) dopamine receptor	2	Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2561	Drugs and targets

1 to 10 of 115

See all 115 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00584701	Pharmacogenomics in Autism Treatment	Phase 2/3	49	2012-07-24	Autism	RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT04292457	Namsos Anaesthesia Children Outcome Study	Not applicable	761		Emergence Delirium	PROPOFOL, SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT01021696	Pain in Patients With Dementia and Behavioural Disturbances	Phase 2/3	352		Dementia, Pain, Agitation	ACETAMINOPHEN, BUPRENORPHINE, MORPHINE, PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT00249145	A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia	Phase 3	349		Dementia, Alzheimer Disease, Dementia, Vascular	RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT02956226	Cannabinoids for Behavioral Problems in Children With ASD	Phase 2	150		Autistic Disorder	CANNABIDIOL, DRONABINOL	Its record names the disease	ClinicalTrials.gov
NCT03862950	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)	Phase 2	125		Fragile X Syndrome, Fragile X Mental Retardation Syndrome, Mental Retardation, X-Linked, Genetic Diseases, X-Linked, Trinucleotide Repeat Expansion, Fra(X) Syndrome, Intellectual Disability, FXS, Neurobehavioral Manifestations, Sex Chromosome Disorders	METFORMIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT03479476	A Trial of Metformin in Individuals With Fragile X Syndrome	Phase 2/3	120		Fragile X Syndrome, Fragile X Mental Retardation Syndrome, Mental Retardation, X Linked, Genetic Diseases, X-Linked, Trinucleotide Repeat Expansion, Fra(X) Syndrome, Intellectual Disability, FXS, Neurobehavioral Manifestations, Sex Chromosome Disorders	METFORMIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00005014	Treatment of Autism in Children and Adolescents	Phase 3	101		Autistic Disorder	RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT00160147	Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type	Phase 3	60		Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type	BIFEPRUNOX	Its record names the disease	ClinicalTrials.gov
NCT01730209	Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex	Phase 2/3	60		Tuberous Sclerosis Complex, TSC Related Cognitive Disability, TSC Related Autism, TSC Related Learning Problems	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
10496251	RESULT	1	PubMed
37811711	DERIVED	1	PubMed
36791792	DERIVED	1	PubMed
34532852	DERIVED	1	PubMed
33536055	DERIVED	1	PubMed
31217257	DERIVED	1	PubMed
29136228	DERIVED	1	PubMed
27524403	DERIVED	1	PubMed
27247487	DERIVED	1	PubMed
26802979	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000708

GET https://conductscience.org/api/diseases/v1/HP_0000708/targets?page=2

API reference For AI assistants